Clinical Trial Update: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a triple regimen of devimistat (CPI-613), bendamustine hydrochloride, and rituximab in relapsed or refractory B-cell non-Hodgkin lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone B-cell Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Devimistat (CPI-613) (devimistat)
• Rituximab (Rituxan) (rituximab)
• Treanda (bendamustine hydrochloride) (bendamustine)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Status: TERMINATED